What is cimepilimab?

Cemiplimab (Cemiplimab) is a programmed death receptor-1 (PD-1) blocking antibody used to treat cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC) and non-small cell lung cancer (NSCLC).

1. Cutaneous squamous cell carcinoma (CSCC): Cimepilimab is suitable for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not suitable for radical surgery or radical radiotherapy.

2. Basal cell carcinoma (BCC):Cimepilimab is indicated for the treatment of patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have been previously treated withhedgehog pathway inhibitors, or for whom hedgehog pathway inhibitors are not suitable.

3. Non-small cell lung cancer (NSCLC): Cimepilimab is indicated in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) without EGFR, ALK or ROS1 abnormalities, and when the patient is not suitable for surgical resection or is confirmed to be locally advanced after chemoradiotherapy or metastasis. As a single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥ 50%], no EGFR, ALK, or ROS1 abnormalities, and are locally advanced when the patient is not a candidate for surgical resection or definitive chemoradiation or metastasis.

Cimepilimab is a type of drug called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the PD-1 protein on the surface of immune cells called T cells. It works by stopping cancer cells from suppressing the immune system. This allows the immune system to attack and kill cancer cells.

Reference materials:https://www.drugs.com/history/libtayo.html